MEDICINAL SIGNIFICANCE OF LOVASTATIN

Nadia Wajid 1, Sanam Saiqa Anwar 1, Fatima Ali 1, Maryam Zahoor 1, Noman Hamid 1, Mehtab Muhammad Aslam 1 and Azib Ali 2

Institute of Molecular Biology and Biotechnology, The University of Lahore 1, Lahore, Pakistan
Bahria Town Hospital Lahore 2, Pakistan

ABSTRACT: Lovastatin is a naturally occurring drug of statin family used for lowering cholesterol. It is found that it can be useful for treatment or management of multiple diseases and has immense medicinal significance. On one side, this drug is used to induce apoptosis in various cancer cells, while other reports indicate that it also promotes cell survival to alleviate certain disease conditions. Antiviral role of lovastatin has also been reported. So, lovastatin, if recommended for any therapy, first requires thorough study as well as experimentations both in-vitro and in-vivo. Current review is systematic, based on search from PubMed by entering key words “Lovastatin cancer, Lovastatin apoptosis and Lovastatin survival” with filter for seven years (2008-2014) data only. It is concluded from the study that Lovastatin has multidirectional role and may be helpful in cancer cells apoptosis as well as survival of certain types of cells. It may be used as anti-viral agent also.

INTRODUCTION: Lovastatin is an anti-hypercholesteremic agent 1 which along with its family members; simvastatin, atorvastatin, pravastatin, rosuvastatin, rosiglitazone, and pioglitazone has been reported as representatives of a therapeutic regimen 2. Lovastatin has been reported to show multidirectional roles in various diseases like cancer, osteoporosis, memory, fatigue, coronary heart disease, diabetes and non-alcoholic fatty liver disease 3. Lovastatin ameliorates blood-retinal barrier breakdown by inhibition of reactive oxygen species by down regulating vascular endothelial growth factor expression 4. Lovastatin demonstrates promising anticancer characteristics through suppression of genes involved in cell division, up-regulation of cell cycle inhibitors, down regulation of cyclins B and D1, aurora kinases A and B, activation of caspase-3 and inhibition of anti-apoptotic factors like Bax, poly-ADP-Ribose Polymerase, Mcl-1 protein 1. Lovastatin helps to block the process of metastasis phenomena and that’s why co-administered with radiation therapy 5.

Statins also act as cytoprotective agents and used in multiple diseases including certain cardiovascular diseases 3, plague 6, dengue 7 and HIV-AIDS 8. Lovastatin has also been reported to protect stem cells against apoptosis 9.

Current study involves collection of variable data reported for multiple actions of lovastatin for various diseases and it was noticed that much of the data reported about lovastatin is as anticancer drug
while its role as cyto-protective agent has been less described.

**Role of Lovastatin in Inhibition of Cancer:**
Statins, because of genetic and behavioral differences of cells have ability to inhibit growth of not only the cancer cells but also that of abnormal hESCs and promote growth of normal hESCs in-vitro. It was observed that statins are safer for use and are not associated with cancer induction.

Lovastatin up regulates miR-33B expression which in turn impairs expression of c-myc thus may be a promising therapeutic option against cancers with c-Myc over expression.

Lovastatin can be used for treatment of malignant mesothelioma as it plays role in prevention of tumor proliferation and angiogenesis by inhibiting VEGFR-2 activation and also VEGF dependent activation of Akt. Lovastatin in combination with VEGF-R2 inhibitor show more robust action against tumor growth.

Lovastatin show duality effect against tumors i.e. at low dose it is found to promote tumor growth whereas at high dose it inhibits tumor progression in a nude mouse cancer model, demanding further studies to rule out this effect. Cancer cells when grown in the presence of lovastatin, they adapt some sort of resistance to lovastatin and exhibit tumor formation ability. However, tumor growth is little bit slower as compared to lovastatin sensitive cells.

**2.1 Oral and Esophageal Squamous cell carcinoma:**
Statins inhibit cell growth and induces cellular apoptosis through a decrease in proliferating cell nuclear antigen (PCNA) and activation of extracellular signal-regulated kinase (ERK), cyclin D1 expression, and increased cleavage of poly(ADP-ribose) polymerase and this way have important role in esophageal squamous cell carcinoma (ESCC) therapy. Lovastatin inhibits ligand mediated dimerization of EGFR and its downstream PI3K/Akt pathway signaling contributing to cytotoxicity of this drug in various types of tumor cells including squamous cell carcinoma cells making it a novel therapeutic agent for tumors. In vitro as well as in nude mouse xenografts, lovastatin has been found to play important role in esophageal cancer cell growth inhibition alone or in combination with curcumin, EGCG by reducing phosphorylated Erk1/2, c-Jun, and cyclooxygenase-2 (COX-2 levels), and activating caspase-3. Lovastatin exhibits cytotoxic effects in squamous cell carcinoma cells also by activating LKB1/AMPK pathway and various other metabolic stress pathways. Arecoline, the major component of areca nut has been found to be involved in pathogenesis of oral cancer via stimulation of Cyr61 protein synthesis and lovastatin may serve as a therapeutic agent for oral cancer as it inhibits the synthesis of Cyr61 protein completely.

**2.2 Polycystic ovary syndrome:**
Lovastatin in association with myo-inositol plays an important role in the treatment of insulin resistance associated with polycystic ovary syndrome (PCOS) via its involvement in cholesterol synthesis.

**2.3 Hepatic tumor:**
Lovastatin shows selective cytotoxic effects against hepatoma cells being most effective for tumor cells. Furthermore, cytotoxic effects of statin are dependent on cell proliferation as evidenced by increased susceptibility of Huh7 cells to lovastatin induced cytotoxicity via reduced p53 expression. Lovastatin induces apoptosis in hepatocellular carcinoma by activating mitochondrial apoptotic pathway.

**2.4 Neurofibromatosis:**
Lovastatin has been found to play an important role in mouse model of neurofibromatosis (NF) via regulation of brain developmental processes and brain activity.

**2.5 Colorectal cancer:**
Lovastatin treatment reduces risk of colorectal cancer development and no significant difference was observed when used for long duration. Lovastatin when used in combination with a COX-2 inhibitor i.e. celecoxib inhibits caveolin-1 and its downstream signaling, contributing to cell survival and this way provide prevention for colorectal cancers.
2.6 Anaplastic thyroid cancer (ARO) cells
Lovastatin exerts antiproliferative effects on anaplastic thyroid cancer (ARO) cells via reducing Rho geranylgeranylation and thus increasing expression and stability of p27 27.Lovastatin induces apoptosis in ovarian cancer cells via mevalonate dependent mechanism and has implication as a potential antitumor drug. It has also been found that antitumor effects of lovastatin synergize in combination with doxorubicin, however this synergy is via mevalonate independent pathway antagonizing drug resistance via inhibiton of P-glycoprotein 36. Lovastatin and atorvastatin are found to induce expression of Cdc42 and Rac1 and activation of JNK pathway leading to enhanced apoptosis of ovarian cancer cells paving the way to development of novel therapy for this cancer 37.

2.7 Prostate Cancer:
Lovastatin down regulates PSA levels by reducing expression of androgen receptor and its activation and thus play important role in inhibition of prostate cancer growth in regular users of lovastatin 28. Statins are of clinical importance for treatment of prostate cancer and clinical trials of statins for prevention of this cancer are being warranted 29. Lovastatin inhibits de novo cholesterol synthesis critical for tumor growth and this way use of this drug has been associated with reduced risk of prostate cancer 30.

2.8 Lung Cancer:
By inhibiting Akt and activating AMPK signaling, Lovastatin increases sensitivity of lung cancer cells to radiotherapy by inducing apoptosis and also impairs survival of cells 31. Lovastatin along with valproic acid acts additively to inhibit growth of malignant pleural mesothelioma mainly by reducing invasion of cells without induction of any effect on cell viability and apoptosis 32.

2.9 Embryonal Carcinoma:
Lovastatin induces differentiation as well as apoptosis of embryonal carcinoma and neuroblastoma via increasing expression of neuronal differentiation markers tyrosine hydroxylase (TH) and growth-associated protein 43 33.

2.10 Liver Carcinogenesis:
Lovastatin has been found to play important role in prevention of liver carcinogenesis in a mouse model and this inhibition is basically due to lovastatin mediated down regulation of ubiquinone synthesis 34.

2.11 Ovarian Cancer Cells:
Lovastatin and simvastatin which are lipophilic statins activate extrinsic as well as intrinsic apoptotic pathways and induce cell death in various gynaecological malignancies in dose and time dependent manner, and further investigations are required for their use as anticancer agents 35. It also suppresses various metabolic pathways including glycolytic pathway, Krebs cycle and lipid biosynthesis pathway. Through these mechanisms, lovastatin exerts its anti-tumor effects on breast cancer cells 40. Lovastatin in combination with a plant alkaloid, berberine exerts antitumor effects on human MDA-MB231 breast cancer. Lovastatin exerts its cytotoxic and cytostatic effects by inhibiting isoprenoid compounds biosynthesis via blocking protein prenylation 41. Gefitinib (EGFR TKI) inhibit phosphorylation of Akt and MAPK and thus proliferation of breast cancer cells. Lovastatin acts in syngernisticity with gefitinib to
increase sensitivity of EGFR TKI-resistant breast cancer cells to this drug treatment by lowering cholesterol levels in lipid rafts altering EGFR mediated Akt signaling 42.

2.13 Pancreatic Cancer:
Statins along with d-delta-Tocotrienol (HMG-CoA reductase downregulators) synergically inhibit mevalonate pathway and ultimately suppress proliferation and tumor growth of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells and so may have implication as potent therapeutic agents for pancreatic cancer 43. Oxysterol binding protein-related protein (ORP) 5 expression plays role in cell invasion by inducing expression of sterol response element binding protein (SREBP) 2 and activate downstream histone deacetylase 5 (HDAC5). Lovastatin in combination with tricostatin A (HDAC inhibitor) demonstrates synergic antitumor effects in pancreatic cancers via inhibiting ORP5 expression and thus invasion and growth of tumor 44. Lovastatin exerts antitumor effects on murine Panc 02 pancreatic cancer cell lines 41.

2.14 Osteosarcoma:
Lovastatin in combination with apomine significantly suppresses osteosarcoma tumor growth in mice by improving inhibition of HMG-CoA reductase in comparison to individual drug usage 45.

Role in cardiovascular diseases:
Statins are extensively used in patients with hyperlipidemic cardiovascular disease and reduce morbidity as well as mortality. Statins affect lipid rejection and vasculature. Statins are helpful in alleviation of atherosclerotic vascular disease because of its anti-inflammatory activity and prevention of thrombosis. These compounds alter the vascular functions by modification of apoptosis of vascular endothelial cells 46.

Lovastatin is a fungal metabolite which performs its function via lowering cholesterol levels 47 and in this way plays important role in the management of dyslipidemia versus other clinical conditions like cancer, osteoporosis, memory, fatigue, coronary heart disease, diabetes, and non-alcoholic fatty liver disease, however, further investigations are still required before using it as a treatment 3. Lovastatin therapy has a significant effect on common carotid artery intima-media thickness (CCA-IMT) decrease 48.

1. Role in plague:
Clinical observations indicated that lovastatin could prevent infections and reduce mortality during severe sepsis hence can reduce the rate of morbidity and mortality in animal models of Plague 6.

2. Role in dengue:
A significant increase in the survival rate was observed when lovastatin was provided in mice affected with dengue virus serotype 2 7.

3. Role in HIV-AIDS:
Lovastatin has also been reported to have antiretroviral effects when administered to HIV-1-infected individuals without highly active antiretroviral therapy 8.

4. Anti-apoptotic effects of lovastatin:
A low dose of lovastatin has been reported to reduce the cytotoxic, anti-proliferative and apoptotic effects of the anticancer drugs on primary human endothelial cells. The effect is considered to be due to a reduced susceptibility of topoisomerases II to its inhibitors and protection from DNA strand break. Stress responses which are triggered by DNA damage like activation of p53 are attenuated by lovastatin eventually leading to increased cell viability 49, 50. When lovastatin was provided in rats before ischemia/reperfusion, it protected the mitochondrial and renal function 51.

One of the important roles of lovastatin was reported in a study of bone marrow transplantation in which morbidity and mortality associated with graft-versus-host disease (GVHD) was reduced after lovastatin treatment. The treatment not only prevented homing of T lymphocytes to lymph nodes and Peyer's patches but also compromised donor-derived T cell proliferation in vivo 52. Interestingly, statins have been suggested to attenuate the stress conditions in cancer treatment caused by certain anti-cancer therapies. They improve the cell viability by enhancing resistance
against the inhibitors of topoisomerases which are responsible for DNA damage hence cell death in the cancer treatment.

7.1 Effect of Lovastatin on Stem Cells:
Lovastatin has been found to have a significant anti-apoptotic effect on MSCs exposed to hypoxia and serum deprivation conditions by activation of the mitochondrial pathway and preventing release of cytochrome-c and activation of caspase-3/CPP32. It was reported that lovastatin has protective effect on bone marrow derived neural stem cells against oxidative stress hence, can be used for the treatment of oxidative stress-mediated neurological diseases. Lovastatin was also reported to improve survival, proliferation and differentiation status of human Wharton’s jelly mesenchymal stem cells’ derived chondrocytes under oxidative stress conditions.

FIG 1: SCHEMATIC REPRESENTATION OF MULTIDIMENSIONAL ROLE OF LOVASTATIN. LOVASTATIN INDUCES APOPTOSIS IN CANCER CELLS. IT ATTENUATES BLOOD RETINAL BARRIER IN CULTURED RETINAL CELLS, IMPROVES RENAL FUNCTION, ATTENUATES CERTAIN VIRAL DISEASES, IMPROVES CARDIOVASCULAR DISEASES AND ALSO IMPROVES CELL SURVIVAL OF STEM CELLS.

Drawbacks:
Lovastatin disturbs various signaling pathways in addition to inhibiting cholesterol biosynthesis like, perturbation of estrogen receptor signaling pathway, altered glutamate metabolism and down regulation of carbonate dehydratase II and disrupted protein ubiquitination pathway.

CONCLUSION: It may be concluded from the data that Lovastatin has multiple roles in different medical conditions. It has multiple positive effects on different disease conditions while on the other hand, certain drawbacks are also reported so care must be taken before deciding it for medication.

CONFLICT OF INTEREST:
Authors declare no conflict of interest.

CONTRIBUTORS:
NW and SSA developed the study plan and finalized the write up, FA, MZ, MMA; NH and AA performed the literature search. All authors approved the final draft.
ACKNOWLEDGEMENTS:  The authors acknowledge The University of Lahore for facilitating the search.

REFERENCES:


International Journal of Pharmaceutical Sciences and Research


